Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00391898
First received: October 24, 2006
Last updated: February 16, 2011
Last verified: February 2011
  Purpose

The study evaluated the efficacy of levodopa/carbidopa/entacapone vs levodopa/carbidopa in patients with Parkinson's disease and early wearing-off with levodopa


Condition Intervention Phase
Parkinson's Disease
Drug: Levodopa/carbidopa/entacapone
Drug: Levodopa/carbidopa
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A 3-month, Multi-center, Double-blind, Randomized Study to Evaluate the Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Impairment of Activities of Daily Living and Early Wearing-off With Levodopa

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living [ADL]) Score From Baseline to Month 3 [ Time Frame: Baseline to end of study (Month 3) ] [ Designated as safety issue: No ]
    The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part II (items 5-17; total score 0-52, calculated as the sum of the individual items) measures the patient's activities of daily living. A lower total score indicates greater symptom control. A negative change score indicates improvement.


Secondary Outcome Measures:
  • Change in the UPDRS Part I (Mentation, Behavior, and Mood) Score From Baseline to Month 3 [ Time Frame: Baseline to end of study (Month 3) ] [ Designated as safety issue: No ]
    The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part I (items 1-4; total score 0-16, calculated as the sum of the individual items) measures the patient's mentation, mood and behavior. A lower total score indicates greater symptom control. A negative change score indicates improvement.

  • Change in the UPDRS Part III (Motor Function) Score From Baseline to Month 3 [ Time Frame: Baseline to end of study (Month 3) ] [ Designated as safety issue: No ]
    The UPDRS is a standardized assessment scale used to measure a patient's disease state. It is completed by a blinded rater. There are 6 parts to the UPDRS. Part III (items 18-31; total score 0-56, calculated as the sum of the individual items) measures the patient's motor function. A lower total score indicates greater symptom control. A negative change score indicates improvement.

  • Change in the UPDRS Part IV (Complications of Therapy) Score From Baseline to Month 3 [ Time Frame: Baseline to end of study (Month 3) ] [ Designated as safety issue: No ]
    Part IV of the UPDRS measures complications the patient may be experiencing with therapy and was only collected at and after the visit at which the first dyskinesia or episode of wearing-off was recorded. Part IV is composed of 3 sections and 11 items: A (32-35, dyskinesia), B (36-39, clinical fluctuations, C (40-42, other complications) (total score 0-23, calculated as the sum of the individual items). A lower total score indicates greater symptom control. A negative change score indicates improvement.

  • Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Month 3 [ Time Frame: Baseline to end of study (Month 3) ] [ Designated as safety issue: No ]
    The PDQ-39 is an instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognitions, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The total score can range from 39 to 195. A lower score indicates better quality of life. A positive change score indicates an improvement.

  • Patient and Investigator Global Evaluation of the Patient [ Time Frame: Baseline to end of study (Month 3) ] [ Designated as safety issue: No ]
    Both the patient and the investigator made an evaluation of the change in the patient's condition by rating the condition of the patient at the end of the study compared to patient's condition at baseline. The rating was made on a scale ranging from -3 to +3: (-3: Very much improved, -2: much improved, -1: mild improvement, 0: no change, +1: mild deterioration, +2: much deterioration, +3: very much deterioration). A negative score indicates improvement.

  • Change on the QUICK Questionnaire (QQ) Score From Baseline to Month 3 [ Time Frame: Baseline to end of study (Month 3) ] [ Designated as safety issue: No ]
    The QQ is a self-administered questionnaire that includes 19 wearing-off (WO) symptoms (motor and non-motor). A positive answer to each of the 19 symptoms is given by patients if they presented with a symptom and the symptom disappeared after the next drug dose. Two positive answers are diagnostic of wearing-off (WO). A negative change score indicates improvement.


Enrollment: 95
Study Start Date: October 2006
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Levodopa/carbidopa/entacapone Drug: Levodopa/carbidopa/entacapone
Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
Active Comparator: Levodopa/carbidopa Drug: Levodopa/carbidopa
Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.

  Eligibility

Ages Eligible for Study:   30 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female patients ages ≥ 30 and ≤ 80 years old.
  2. A clinical diagnosis of idiopathic Parkinson's disease.
  3. Taking a stable dose of levodopa/carbidopa (≥ 300 and ≤ 600mg) for a period of at least 1 month prior to study entry.
  4. Must be using any of the following levodopa/carbidopa standard formulation levodopa/carbidopa 100/25mg dose in any intake of the day.

    • 1 full tablet, and/or
    • 1½ tablets The patient can also be using, for a period of at least 1 month prior to study entry, 1 tablet of the controlled release formulation of levodopa/carbidopa 100/25 mg (marketed in Spain as Sinemet Plus retard) or 1 tablet the controlled release formulation of levodopa/carbidopa 200/50 mg (marketed in Spain as Sinemet retard) in each intake, at different doses.
  5. Must have early end-of-dose wearing-off defined by >= 2 or <=7 positive responses to the QUICK questionnaire.
  6. Must have a minimum UPDRS part II (ADL) score of 9.
  7. Patients without dyskinesia or with mild dyskinesia.
  8. Female patients must be either post-menopausal or using one or more acceptable methods of contraception.
  9. Must be capable of satisfying the requirements of the protocol and must be willing and able to give informed consent according to legal requirements.

Exclusion Criteria:

  1. Previous or current use of entacapone.
  2. History, signs, or symptoms suggesting the diagnosis of secondary or atypical parkinsonism.
  3. Unstable Parkinson's disease patients.
  4. Patients who experience severe dyskinesia.
  5. The following levodopa/carbidopa doses and strengths are not permitted:

    • Patients taking ½ tablet of standard formulation levodopa/carbidopa 100/25
    • Patients taking standard formulation levodopa/carbidopa 100/10 or 250/25
    • Patients taking fewer than 3 or more than 6 daily intakes of standard formulation levodopa/carbidopa 100/25 (fewer than 300mg or more than 600mg of levodopa)
  6. Patients with hallucinations or psychiatric diseases related to levodopa or dopamine agonists intake. Patients with major depression.
  7. Female patients who are pregnant, trying to become pregnant or nursing (lactating) an infant.
  8. Concomitant treatment with MAO-inhibitors (except selegiline up to 10mg/day), rotigotine or neuroleptics, within 60 days prior to the screening visit.
  9. Patients with a previous history of Neuroleptic Malignant Syndrome (NMS) and/or non-traumatic rhabdomyolysis.
  10. Participated in another trial of an investigational drug/device within the last 30 days prior to study entry.
  11. Patients who have a history of poor compliance or are in the Investigator's judgment unlikely to comply with medical regimens or study requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00391898

Locations
Spain
Hospital Universitario Principe de Asturias
Alcalá de Henares, Madrid, Spain, 28805
Fundación Hospital de Alcorcón
Alcorcón (Madrid, Spain, 28922
Hospital General de Alicante
Alicante, Spain, 03010
Hospital Vall d'Hebron
Barcelona, Spain, 08025
Corporació Sanitària Parc Taulí Sabadell
Barcelona, Spain, 08208
Hospital Clínic i Provincial de Barcelona
Barcelona, Spain, 08036
Centro Médico Teknon
Barcelona, Spain, 08022
Hospital de la Santa Creu i de Sant Pau
Barcelona, Spain, 08025
Hospital General Yagüe
Burgos, Spain, 09005
Hospital Universitario Virgen de las Nieves
Granada, Spain, 18012
Hospital Universitari Bellvitge Princeps d'Espanya
L'Hospitalet de Llobregat , Barcelona, Spain, 08907
Hospital Juan Canalejo
La Coruña, Spain, 15002
Clínica Ruber
Madrid, Spain, 28006
Hospital General Universitario Gregorio Marañon
Madrid, Spain, 28007
Hospital Universitario La Paz
Madrid, Spain, 28046
Hospital 12 de Octubre
Madrid, Spain, 28041
Hospital Clínico San Carlos
Madrid, Spain, 28040
Fundación Jiménez Díaz
Madrid, Spain, 28040
Universitaria de Navarra
Pamplona, Spain, 31008
Policlínica Gipuzkoa
San Sebastian, Spain, 20009
Hospital General de Catalunya
Sant Cugat del Valles, Barcelona, Spain, 08195
Hospital Universitario Virgen del Rocio
Sevilla, Spain, 41013
Hospital Mutua de Terrassa
Terrassa, Barcelona, Spain, 08221
Hospital Clínico Universitario de Valencia
Valencia, Spain, 46010
Hospital Gral. de Valencia
Valencia, Spain, 46014
Hospital Universitario de la Fe
Valencia, Spain, 46009
Sponsors and Collaborators
Novartis
Investigators
Principal Investigator: Eduard Tolosa-Sarró, Dr. Hospital Clínic i Provincial de Barcelona
  More Information

No publications provided

Responsible Party: External Affairs, Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00391898     History of Changes
Other Study ID Numbers: CELC200AES03
Study First Received: October 24, 2006
Results First Received: January 4, 2011
Last Updated: February 16, 2011
Health Authority: Spain: Agencia Española del Medicamento y Productos Sanitarios. Ministerio de Sanidad y Consumo

Keywords provided by Novartis:
Parkinson's disease, adults, levodopa/carbidopa/entacapone, wearing-off, activities of daily living

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Levodopa
Carbidopa
Entacapone
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Enzyme Inhibitors

ClinicalTrials.gov processed this record on September 18, 2014